Vertex Pharmaceuticals Q1 EPS Hits $4.47 Despite $2.99B Revenue Miss, Barclays Sees 45% Upside
Barclays upped its price target for Vertex Pharmaceuticals to $615 from $607, implying a 44.92% upside. In Q1, Vertex posted $2.99 billion in revenue, just below projections, while delivering adjusted earnings of $4.47 per share and seeing new products contribute over 25% of growth.
1. Analyst Raises Price Target
Barclays increased its price target for Vertex Pharmaceuticals to $615 from $607, reflecting growing confidence in the company’s long-term growth prospects and signaling a potential 44.92% upside.
2. Q1 Financial Results
In the first quarter, Vertex recorded $2.99 billion in revenue, slightly under the $3.03 billion forecast, while adjusted earnings reached $4.47 per share versus an expected $4.31, marking a clear earnings beat.
3. New Product Sales Driving Growth
Sales of the new cystic fibrosis therapy surged nearly eightfold, and combined revenue from CASGEVY and JOURNAVX accounted for over 25% of the quarter’s growth, underscoring the impact of Vertex’s expanding pipeline.
4. Historical Performance Consistency
Vertex has outperformed revenue estimates for four consecutive quarters and surpassed EPS expectations in three of the last four periods, demonstrating sustained financial strength and operational execution.